Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Connect Tissue Res. 2017 May 19;59(2):129–146. doi: 10.1080/03008207.2017.1313248

Figure 3: ERK1/2 and JNK1/2 activation mediate ASC osteogenesis in alternate osteoinduction conditions.

Figure 3:

Activation levels of ERK1/2 and JNK1/2 following osteogenic induction of Category 3 ASC populations (n=6) for either 14 (Panel A) or 21 days (Panel B) is shown after conventional OM induction, in addition to induction with OM containing 1,25-dihydroxyvitamin D3 (OMVD) or hydroxycortisol (OMcortisone) in lieu of dexamethasone. ERK1/2 and JNK1/2 activation levels (pERK1/2, pJNK1/2) are shown normalized to non-induced controls (Kinase Activation -fold change vs. CM). Activation levels of ERK1/2 and JNK1/2 following 21 days induction of Category 1 and 3 ASC populations (n=8) in OM lacking dexamethasone (OMNoDex) are shown compared with non-induced controls (Panel C). Average mineralization levels versus controls are given for each condition. * indicates a significance difference (p<0.05; t-test) versus CM controls.